AI Co Pilot to Revolutionize Structural Heart Care

A Landmark Collaboration in Heart Care

The Cleveland Clinic, a global leader in healthcare, has announced a significant partnership with DASI Simulations. The two organizations are joining forces to co-develop the next generation of AI-powered predictive modeling solutions designed to transform the treatment of structural heart diseases. As part of this agreement, Cleveland Clinic will also integrate DASI's current technology to enhance procedure planning for its patients.

What is TAVR and How Will AI Help

At the heart of this innovation is the Transcatheter Aortic Valve Replacement (TAVR) procedure, a minimally invasive technique that replaces a diseased aortic valve without requiring open-heart surgery. This collaboration aims to elevate the standard of care for this already advanced procedure.

"We’re committed to innovating in the cardiovascular field for both patients and providers, and this relationship will elevate the standard of TAVR care for heart care providers across the country," said Dr. Samir Kapadia, chairman of Cardiovascular Medicine at Cleveland Clinic. "Developing our models to guide TAVR during the procedure with the help of AI will allow us to further enhance the safety of the procedure and ensure optimal valve selection."

The Vision An AI Co-Pilot for Surgeons

Over the next two years, DASI and Cleveland Clinic will work to create a groundbreaking AI technology that can provide real-time assistance to doctors during cardiac procedures. By merging Cleveland Clinic's vast clinical expertise and data with DASI's sophisticated AI models, the ultimate goal is to build the world’s first AI-powered “co-pilot” system for catheterization labs.

Pioneering a New Era of Personalized Medicine

Leaders from both organizations see this partnership as a pivotal moment for cardiovascular care. "Partnering with Cleveland Clinic allows us to bring the power of AI-driven, physics-based simulation directly into current clinical practice,” stated DASI Founder and CEO Teri Sirset. “Together, we are pioneering a new era of personalized medicine... transforming how structural heart procedures are planned and executed to improve patient outcomes."

This sentiment was echoed by Dr. Lakshmi (Prasad) Dasi, founder and chief technology officer of DASI. “This partnership marks a major milestone for DASI and for the field. It validates our vision of advanced predictive modeling as the future of decision-making in structural heart therapies... With our next-generation products, I see us truly democratizing decision-making in structural heart procedures—enabling the highest quality care, improving outcomes and ultimately reducing healthcare costs.”

Building on Proven Technology

The foundation for this future development is DASI Simulations' current technology—a novel, AI-powered medical platform that converts a standard CT scan into a four-dimensional predictive environment. This allows physicians to personalize their treatment strategy to optimize results for each unique patient.

The company’s flagship product, PrecisionTAVI™, is the only FDA-cleared solution with a CMS reimbursement code in this specialized field. This powerful combination of AI and computational modeling has already demonstrated a consistent ability to improve patient outcomes. In addition to the collaboration, Cleveland Clinic is also an investor in DASI Simulations and may benefit financially from the technology's commercial success.